Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTyratech Regulatory News (TYR)

  • There is currently no data for TYR

Replacement: Migration of Shares

7 Dec 2011 10:44

RNS Number : 5145T
TyraTech, Inc.
07 December 2011
 



The following announcement replaces the Migration of Shares and Block Listing Review announcement RNS 4745T released at 07:00 a.m. on 7 December 2011. The exact number of common shares which have migrated, being 11,144,809, has been included. All other text remains the same. A correction of the full announcement is below.

 

 

7 December 2011

 

TYRATECH, INC.

("TyraTech" or the "Company")

 

Migration of Shares, Block Listing Interim Review

and Total Shares in Issue

 

Migration of Shares

 

TyraTech, Inc. (AIM: TYR), a natural life sciences company announces that 11,144,809 common shares in the Company on its restricted "TYR" trading line have now migrated to its unrestricted trading line "TYRU".

 

Following the migration of these shares, which is expected to occur on 13 December 2011, the Company will have a total of 51,856,218 common shares admitted to AIM (excluding those shares admitted and not allotted under the Block listing announced on 25 February 2011), of which 40,063,896 will continue to trade under the symbol TYR in a restricted manner as permitted by Regulation S of the U.S. Securities Act of 1993 (the "Securities Act") and 11,792,322 will trade under the symbol TYRU in an unrestricted manner pursuant to an exemption provided under the Securities Act. CREST settlement will not be available for trades in TYR shares.

 

Block Listing Interim Review

 

Name of company:

TyraTech, Inc.

Name of scheme:

2007 Equity Compensation Plan of the Company

Period of return:

From: 25 February 2011 To: 7 December 2011

Number and class of securities not issued under the scheme at the start of the period

5,183,746 common shares

Number of securities issued under the scheme during the period

18,750

Balance under the scheme of securities not yet issued at the end of the period

5,164,996

Number and class of securities originally admitted and the date of admission

5,183,746 common shares on 2 March 2011

Name of contact:

Peter Jerome

Telephone number of contact:

+1 919 415 4280

 

Total Shares in Issue

 

The Company wishes to correct the announcements made on 18 May 2010 (Update to Fundraising) and 19 May 2010 (Result of Special Meeting) for the amount of common shares issued to subscribers as part of the subscription announced on 10 May 2010. The announcements indicated that 24,444,444 common shares were issued to subscribers. However, the actual number of common shares issued to subscribers was 24,443,888.

 

Therefore, the Company has a total of 51,856,218 common shares admitted to AIM (excluding those shares admitted and not allotted under the block listing announced on 25 February 2011).

 

 

For further information please contact:

 

TyraTech Inc.

Alan Reade, Executive Chairman

Peter Jerome, Chief Financial Officer

 

 

Tel: +1 919 415 4310

Tel: +1 919 415 4280

Brewin Dolphin Limited (Nominated Adviser)

Robert Beenstock

 

Tel: +44 845 213 1000

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBGBDDCXGBGBR
Date   Source Headline
8th Nov 20185:25 pmRNSTyratech
2nd Nov 20185:30 pmRNSTyratech
31st Oct 20183:01 pmRNSResult of Special Meeting, Cancellation from AIM
25th Oct 20187:00 amRNSSpecial Meeting and Acquisition Update
18th Oct 20183:00 pmRNSNominee accounts
9th Oct 20182:23 pmRNSPosting of Proxy Statement and Timetable Update
5th Oct 201810:05 amRNSUpdate
28th Sep 20188:50 amRNSInterim Results
28th Sep 20187:00 amRNSConditional Merger Agreement Signed with AMVAC
23rd May 20187:00 amRNSFinal Results
9th May 20187:00 amRNSProgress in 2018 on products and milestones
3rd May 20187:00 amRNSChange of Adviser
24th Jan 20185:44 pmRNSHolding(s) in Company
18th Jan 20187:00 amRNSHolding(s) in Company
15th Jan 20187:00 amRNSResult of Tender Offer
11th Jan 20181:08 pmRNSTR-1
9th Jan 20185:01 pmRNSTR-1
5th Jan 20187:00 amRNSResult of Tender Offer
28th Dec 20177:00 amRNSResult of Special Meeting
4th Dec 20177:00 amRNSTender Offer to Shareholders and Notice of Meeting
12th Sep 20177:00 amRNSInterim Results for Six Months Ended 30 June 2017
24th Aug 20177:00 amRNSCOMPANY UPDATE AND DATE OF INTERIM RESULTS
4th Jul 20172:29 pmRNSJoint Development and License Agreement
29th Jun 20177:00 amRNSResult of AGM
7th Jun 20177:00 amRNSTYR TR-1: Notification of major interest in shares
9th May 20177:00 amRNSResults for the Year Ended 31 December 2016
28th Apr 20173:24 pmRNSFurther re Notice of Final Results
22nd Mar 20178:57 amRNSTR-1: Notification of major interest in shares
9th Feb 20177:00 amRNSPre-close Trading Update
19th Sep 20163:59 pmRNSDirector/PDMR Shareholding
15th Sep 20161:18 pmRNSDirectors' Dealings
13th Sep 20167:00 amRNSInterim Results for Six Months Ended 30 June 2016
28th Jul 20167:00 amRNSPre Close Trading Update
8th Jun 20163:22 pmRNSResult of AGM and Board Change
22nd Apr 20161:57 pmRNSDirectors' Dealings
15th Apr 201612:03 pmRNSAward of Share Options
15th Apr 201611:57 amRNSDirectors' Dealings
14th Apr 20167:00 amRNSDirectors' Dealings
11th Apr 20167:00 amRNSAppointment of José Barella as Chairman
4th Apr 20167:00 amRNSNotice of Preliminary Results
3rd Feb 201612:31 pmRNSHolding(s) in Company
1st Feb 20161:08 pmRNSDirector's Dealings
1st Feb 20167:00 amRNSPre-close Trading Update
20th Jan 20167:00 amRNSAppointment of Erica H. Boisvert as CFO
13th Jan 20167:00 amRNSNew Product Range Launch & Distribution Agreement
17th Dec 20154:01 pmRNSTR-1: Notification of Major Interest in Shares
4th Dec 201511:00 amRNSTR-1: Notification of major interest in shares
26th Nov 201512:51 pmRNSTR-1: Notification of Major Interest in Shares
16th Nov 20155:01 pmRNSResult of Special Meeting & Director Shareholdings
4th Nov 20157:00 amRNSPlacing and Subscription to raise £3.16m

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.